Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 billion in Q4 2025 revenue.

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi, or combining both.

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi, or combining both.

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion in revenue, respectively.

The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology portfolio increased 9 percent year over year.

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a deadline it hopes to hold off a bit longer.

CIRM will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" of platform approaches.

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat genetic hearing loss.

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle cell lymphoma patients.

The nonprofit biotech recently licensed the gene therapy from Boston Children's Hospital and plans to bring it to low- and middle-income countries.

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after unexpected FDA feedback.

Medicare lab spending totaled $8.4 billion in 2024, up 5 percent year over year, with $3.6 billion of that spent on genetic testing, an increase of 20 percent over 2023.

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.

While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.

The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in hypercholesterolemia.

While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to cancer and rare disease mRNA programs.

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, researchers are calling for prospective validation.

Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and showed its potential as a non-invasive companion diagnostic.

Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.

If the provision passes as part of the bill, it would address a major priority of many firms in the MCED business.

The company discussed plans to leverage MRD in drug development during a call to discuss Q4 and full-year 2025 financials.

All patients with autoimmune hemolytic anemia in a small study initially achieved remission, though two eventually relapsed, opening the way for more research.

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in stiff person syndrome.

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this year.

The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in patients with gastroesophageal and pancreatic cancers.

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in stiff person syndrome.

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this year.

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying treatment and not just a seizure reducer.

The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in patients with gastroesophageal and pancreatic cancers.

At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel its growth.

The firm said at the JP Morgan Healthcare Conference that a pivotal Phase III study, testing daraxonrasib in RAS-mutant pancreatic cancer, will read out in the first half of 2026.

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying treatment and not just a seizure reducer.

The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer later this year.

The firm said at the JP Morgan Healthcare Conference that a pivotal Phase III study, testing daraxonrasib in RAS-mutant pancreatic cancer, will read out in the first half of 2026.

Two antibody-drug conjugates are among 10 programs that the company expects to fuel its growth, the company said.

The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.

The firm's share price fell after a presentation at the conference revealed lower-than-expected Elevidys sales.

The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer later this year.

The company highlighted multiple myeloma and CAR T therapies as growth drivers and announced two new US manufacturing facilities.

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months compared to Tecentriq alone.

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how politics will impact innovation long term.